Englander Institute for Precision Medicine
Found 811 results
Author Title Type [ Year(Asc)]
Filters: Corrigendum-whole-genome-and-transcriptome-analysis-pancreatic-acinar-cell-carcinoma is   [Clear All Filters]
2016
Rennert H, Eng K, Zhang T, Tan A, Xiang J, Romanel A, Kim R, Tam W, Liu Y-C, Bhinder B et al..  2016.  Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.. NPJ Genom Med. 1:16019-.
Beltran H, Prandi D, Mosquera JMiguel, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BVSK, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 22(3):298-305.
Meller S, VAN Ellen A, Gevensleben H, Bicker A, Hankeln T, Gorr TA, Sailer V, Dröge F, Schröck F, Bootz F et al..  2016.  Ectopic Myoglobin Expression Is Associated with a Favourable Outcome in Head and Neck Squamous Cell Carcinoma Patients.. Anticancer Res. 36(12):6235-6241.
Pauli C, Puca L, Mosquera JMiguel, Robinson BD, Beltran H, Rubin MA, Rao RA.  2016.  An emerging role for cytopathology in precision oncology.. Cancer Cytopathol. 124(3):167-73.
Ribback S, Sailer V, Böhning E, Günther J, Merz J, Steinmüller F, Utpatel K, Cigliano A, Peters K, Pilo MG et al..  2016.  The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.. Int J Mol Sci. 17(10)
Rubin MA, Girelli G, Demichelis F.  2016.  Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.. Eur Urol. 69(4):557-560.
Ceder Y, Bjartell A, Culig Z, Rubin MA, Tomlins S, Visakorpi T.  2016.  The Molecular Evolution of Castration-resistant Prostate Cancer.. Eur Urol Focus. 2(5):506-513.
Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T et al..  2016.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.. Cancer Cell. 30(4):563-577.
Gevensleben H, Holmes EEva, Goltz D, Dietrich J, Sailer V, Ellinger J, Dietrich D, Kristiansen G.  2016.  PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.. Oncotarget. 7(48):79943-79955.
Sailer V, Holmes EEva, Gevensleben H, Goltz D, Dröge F, de Vos L, Franzen A, Schröck F, Bootz F, Kristiansen G et al..  2016.  PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.. Oncotarget. 7(46):75827-75838.
Holmes EEva, Goltz D, Sailer V, Jung M, Meller S, Uhl B, Dietrich J, Röhler M, Ellinger J, Kristiansen G et al..  2016.   promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy.. Clin Epigenetics. 8:104.